vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and MetroCity Bankshares, Inc. (MCBS). Click either name above to swap in a different company.

BICYCLE THERAPEUTICS PLC is the larger business by last-quarter revenue ($48.0M vs $43.7M, roughly 1.1× MetroCity Bankshares, Inc.). MetroCity Bankshares, Inc. runs the higher net margin — 50.5% vs -42.0%, a 92.5% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs 23.6%). MetroCity Bankshares, Inc. produced more free cash flow last quarter ($37.0M vs $-19.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs 15.7%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

Metro City Bank is a Korean-American bank based in Doraville, Georgia and offers personal and commercial banking services. It is the largest Korean-American bank to not be based out of Los Angeles, California. It currently operates a total of 19 branches in Texas, New York, New Jersey, Virginia, Georgia, Alabama, and Florida.

BCYC vs MCBS — Head-to-Head

Bigger by revenue
BCYC
BCYC
1.1× larger
BCYC
$48.0M
$43.7M
MCBS
Growing faster (revenue YoY)
BCYC
BCYC
+1169.7% gap
BCYC
1193.3%
23.6%
MCBS
Higher net margin
MCBS
MCBS
92.5% more per $
MCBS
50.5%
-42.0%
BCYC
More free cash flow
MCBS
MCBS
$56.9M more FCF
MCBS
$37.0M
$-19.9M
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
15.7%
MCBS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCYC
BCYC
MCBS
MCBS
Revenue
$48.0M
$43.7M
Net Profit
$-20.2M
$18.1M
Gross Margin
Operating Margin
-51.5%
52.8%
Net Margin
-42.0%
50.5%
Revenue YoY
1193.3%
23.6%
Net Profit YoY
61.1%
11.7%
EPS (diluted)
$-0.29
$0.69

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
MCBS
MCBS
Q4 25
$48.0M
$43.7M
Q3 25
$11.7M
$38.0M
Q2 25
$2.9M
$37.9M
Q1 25
$10.0M
$36.0M
Q4 24
$3.7M
$35.4M
Q3 24
$2.7M
$36.9M
Q2 24
$9.4M
$36.3M
Q1 24
$19.5M
$32.7M
Net Profit
BCYC
BCYC
MCBS
MCBS
Q4 25
$-20.2M
$18.1M
Q3 25
$-59.1M
$17.3M
Q2 25
$-79.0M
$16.8M
Q1 25
$-60.8M
$16.3M
Q4 24
$16.2M
Q3 24
$-50.8M
$16.7M
Q2 24
$-39.8M
$16.9M
Q1 24
$-26.6M
$14.6M
Operating Margin
BCYC
BCYC
MCBS
MCBS
Q4 25
-51.5%
52.8%
Q3 25
-558.6%
62.8%
Q2 25
-2965.8%
62.4%
Q1 25
-703.7%
61.3%
Q4 24
58.9%
Q3 24
-2385.9%
61.4%
Q2 24
-498.3%
64.4%
Q1 24
-162.4%
62.6%
Net Margin
BCYC
BCYC
MCBS
MCBS
Q4 25
-42.0%
50.5%
Q3 25
-503.7%
45.5%
Q2 25
-2703.8%
44.4%
Q1 25
-608.9%
45.3%
Q4 24
54.0%
Q3 24
-1898.4%
45.3%
Q2 24
-425.3%
46.7%
Q1 24
-136.0%
44.8%
EPS (diluted)
BCYC
BCYC
MCBS
MCBS
Q4 25
$-0.29
$0.69
Q3 25
$-0.85
$0.67
Q2 25
$-1.14
$0.65
Q1 25
$-0.88
$0.63
Q4 24
$0.64
Q3 24
$-0.74
$0.65
Q2 24
$-0.77
$0.66
Q1 24
$-0.62
$0.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
MCBS
MCBS
Cash + ST InvestmentsLiquidity on hand
$628.1M
$383.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$610.0M
$544.2M
Total Assets
$717.6M
$4.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
MCBS
MCBS
Q4 25
$628.1M
$383.7M
Q3 25
$648.3M
$227.2M
Q2 25
$721.5M
$286.0M
Q1 25
$793.0M
$285.1M
Q4 24
$879.5M
$249.9M
Q3 24
$890.9M
$291.2M
Q2 24
$961.4M
$327.9M
Q1 24
$457.0M
$258.8M
Total Debt
BCYC
BCYC
MCBS
MCBS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$30.9M
Q1 24
$30.8M
Stockholders' Equity
BCYC
BCYC
MCBS
MCBS
Q4 25
$610.0M
$544.2M
Q3 25
$618.5M
$445.9M
Q2 25
$668.9M
$436.1M
Q1 25
$740.3M
$428.0M
Q4 24
$793.1M
$421.4M
Q3 24
$831.0M
$407.2M
Q2 24
$873.8M
$407.2M
Q1 24
$356.0M
$396.6M
Total Assets
BCYC
BCYC
MCBS
MCBS
Q4 25
$717.6M
$4.8B
Q3 25
$764.0M
$3.6B
Q2 25
$832.2M
$3.6B
Q1 25
$883.9M
$3.7B
Q4 24
$956.9M
$3.6B
Q3 24
$996.7M
$3.6B
Q2 24
$1.1B
$3.6B
Q1 24
$547.1M
$3.6B
Debt / Equity
BCYC
BCYC
MCBS
MCBS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.04×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
MCBS
MCBS
Operating Cash FlowLast quarter
$-19.3M
$37.7M
Free Cash FlowOCF − Capex
$-19.9M
$37.0M
FCF MarginFCF / Revenue
-41.5%
84.7%
Capex IntensityCapex / Revenue
1.2%
1.5%
Cash ConversionOCF / Net Profit
2.08×
TTM Free Cash FlowTrailing 4 quarters
$-252.0M
$79.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
MCBS
MCBS
Q4 25
$-19.3M
$37.7M
Q3 25
$-71.2M
$16.5M
Q2 25
$-72.8M
$14.5M
Q1 25
$-86.4M
$11.9M
Q4 24
$-164.7M
$63.5M
Q3 24
$-39.8M
$-11.5M
Q2 24
$-44.6M
$19.4M
Q1 24
$-70.9M
$36.4M
Free Cash Flow
BCYC
BCYC
MCBS
MCBS
Q4 25
$-19.9M
$37.0M
Q3 25
$-71.8M
$16.2M
Q2 25
$-73.3M
$14.3M
Q1 25
$-87.0M
$11.8M
Q4 24
$-166.0M
$62.2M
Q3 24
$-40.3M
$-11.8M
Q2 24
$-45.0M
$19.0M
Q1 24
$-70.9M
$36.1M
FCF Margin
BCYC
BCYC
MCBS
MCBS
Q4 25
-41.5%
84.7%
Q3 25
-612.3%
42.7%
Q2 25
-2509.7%
37.8%
Q1 25
-871.7%
32.9%
Q4 24
-4475.7%
175.8%
Q3 24
-1504.7%
-31.9%
Q2 24
-481.2%
52.4%
Q1 24
-362.9%
110.6%
Capex Intensity
BCYC
BCYC
MCBS
MCBS
Q4 25
1.2%
1.5%
Q3 25
5.7%
0.7%
Q2 25
17.1%
0.3%
Q1 25
6.1%
0.2%
Q4 24
33.3%
3.6%
Q3 24
16.3%
0.8%
Q2 24
4.5%
1.0%
Q1 24
0.1%
0.7%
Cash Conversion
BCYC
BCYC
MCBS
MCBS
Q4 25
2.08×
Q3 25
0.95×
Q2 25
0.86×
Q1 25
0.73×
Q4 24
3.91×
Q3 24
-0.69×
Q2 24
1.14×
Q1 24
2.49×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons